Calidi (CLDI) Biotherapeutics announced the succession of its Chief Executive Officer, Allan Camaisa, to Eric Poma, Ph.D., who was appointed as CEO and member of the Board of Directors of Calidi, effective April 22, 2025. Camaisa will continue to serve as a member of the Board.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLDI:
- Calidi announces FDA clearance of IND application for CLD-201
- Calidi appoints Guy Travis Clifton as CMO, Consultant, Advisor
- Calidi Biotherapeutics Appoints New Chief Medical Officer
- Calidi Biotherapeutics Reports 2024 Financial Results and Progress
- Calidi reports Q4 EPS Q4 EPS (27c) vs (23c) last year